Papua New Guinea Expands Access to Six-Month, All-Oral Treatment for Drug-Resistant Tuberculosis
Papua New Guinea (PNG) has begun rolling out the six-month, WHO-endorsed BPaL/M treatment regimens for DR-TB. This change is expected to improve treatment experiences and outcomes, and save money.
Breakthrough in Tuberculosis Treatment: Major Price Cuts for Life-Saving Drugs
25% price reduction of key DR-TB drug, pretomanid, announced by TB Alliance, Lupin Limited, and Stop TB Partnership’s Global Drug Facility (GDF). Pretomanid price falls below $1 per day; BPaLM price falls below $2 per day.